Navigation Links
Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it plans to report its third quarter financial results on Thursday, November 6, 2008 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PST, (4:30 p.m. EST) which will be simultaneously broadcast over the Internet.

Jonathan Lim, M.D., President and Chief Executive Officer, Gregory Frost, Ph.D., Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, David Ramsay, Vice President and Chief Financial Officer, and Robert Uhl, Senior Director, Investor Relations, will participate in the call and provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers and providing the conference ID # 71335335. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's web site at http://www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need.

Halozyme Contact

Robert H. Uhl

Senior Director, Investor Relations

(858) 704-8264

ruhl@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at Upcoming Investor Conferences
2. Halozyme Therapeutics to Host Research Day for Investors and Analysts
3. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
4. Halozyme Therapeutics to Present at Upcoming Investor Conferences
5. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... CA (PRWEB) , ... July 20, 2017 , ... Corporate ... governance at its 27th annual Director of the Year Awards. , The awards will ... La Jolla. This annual event celebrates directors who have made significantly positive contributions ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or ... needs and has the capabilities to properly execute your job can take many hours ... is a sourcing portal designed to showcase the company’s capabilities and core custom ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... Blood centers ... patients across the region. Nationally, summer is a struggle for community blood centers as ... the San Antonio Chamber of Commerce is teaming up with the ...
(Date:7/17/2017)... ... 17, 2017 , ... Whitehouse Laboratories is excited to announce ... full series of ISO 80369 standard test procedures. The ISO 80369 series of ... delivery systems. With this recent expansion, Whitehouse Labs becomes one of the only ...
Breaking Biology Technology:
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
Breaking Biology News(10 mins):